Taking this report together with our published literature, we proposed that NCAPD3 affected different stages of PCa through specific pathways, and these are still required to be confirmed by more high‐quality experiments, which could help to broaden the therapeutic strategies for prostate cancer. Here, NCAPD3 is linked to prostate carcinoma.